The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study

Atherosclerosis

Volumn 126, Issue 2, 1996, Pages 299-303

  Herrmann, Stefan Martin ^a   Blanc, Hervé ^a   Poirier, Odette ^a   Arveiler, Dominique ^c   Luc, Gerald ^e   Evans, Alun ^b   Marques Vidal, Pedro ^d   Bard, Jean Marie ^e   Cambien, François ^a  

^a INSERM   (France)

^b MONICA Project   (United Kingdom)

^c MONICA Project   (France)

^d MONICA Project   (France)

^e MONICA Project   (France)

Author keywords

Atherosclerosis; Myocardial infarction; Paraoxonase; Polymorphism

Indexed keywords

ARYLESTERASE; PEROXIDASE;

ADULT; ANGIOCARDIOGRAPHY; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030601629     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05917-5     Document Type: Article

References (12)

1. Schmiegelow K., Eiberg H., Tsui L-Cet al. Linkage between the loci for cystic fibrosis and paraoxonase. Clin Genet. 29:1986;374.
2. Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos. 30(10):1991;141.
3. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 3:1993;73.
4. Adkins S, Gan KN, Mody M, La Du BN Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191 for the respective A or B allozymes. Am J Hum Genet. 52:1993;598.
5. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 40:1991;277.
6. Hegele RA, Brunt JH, Connelly PW A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 15:1995;89.
7. Ruiz J, Blanché H, James RWet al. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869.
8. Mackness MI, Arrol S, Abbot C, Durrington PN Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:1993;129.
9. WHO MONICA Project Principal Investigators The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration. J Clin Epidemiol. 41:1988;105.
10. Parra HJ, Arveiler D, Evans AEet al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arterioscler Thromb. 12:1992;701.
11. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 32:1986;671.
12. Mackness MI, Durrington PN Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet. 346:1995;856.